Publications

 

2017

  1. Kitagawa K, Shigemura K, Onuma KI, Nishida M, Fujiwara M, Kobayashi S, Yamasaki M, Nakamura T, Yamamichi F, Shirakawa T, Tokimatsu I, Fujisawa M. Improved bacterial identification directly from urine samples with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Clin Lab Anal. 2017 Jul 24. doi: 10.1002/jcla.22301. [Epub ahead of print]

  2. Saito H, Kitagawa K, Yoneda T, Fukui Y, Fujsawa M, Bautista D, Shirakawa T. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer Gene Ther. 2017 Jun 16. doi: 10.1038/cgt.2017.21. [Epub ahead of print]

  3. Osawa K, Shigemura K, Nukata Y, Kitagawa K, Yamamichi F, Yoshida H, Shirakawa T, Arakawa S, Fujisawa M. penA, ponA, porB1, and mtrR Mutations and Molecular Epidemiological Typing of Neisseria gonorrhoeae with Decreased Susceptibility to Cephalosporins. Antimicrob Agents Chemother. 2017 Jul 25;61(8). pii: e01174-17. doi: 10.1128/AAC.01174-17. Print 2017 Aug.

  4. Kitagawa K, Oda T, Saito H, Araki A, Gonoi R, Shigemura K, Hashii Y, Katayama T, Fujisawa M, Shirakawa T. Development of oral cancer vaccine using recombinant Bifidobacterium displaying Wilms' tumor 1 protein.  Cancer Immunol Immunother. 2017 Mar 15. doi: 10.1007/s00262-017-1984-0.

  5. Kitagawa K, Omoto C, Oda T, Araki A, Saito H, Shigemura K, Katayama T, Hotta H, Shirakawa T. Oral Combination Vaccine, Comprising Bifidobacterium Displaying Hepatitis C Virus Nonstructural Protein 3 and Interferon-α, Induces Strong Cellular Immunity Specific to Nonstructural Protein 3 in Mice. Viral Immunol. 2017 Jan 23. doi: 10.1089/vim.2016.0111.

2016

  1. Iijima Y, Oundo JO, Hibino T, Saidi SM, Hinenoya A, Osawa K, Shirakawa T, Osawa R, Yamasaki S. High Prevalence of Diarrheagenic Escherichia coli among Children with Diarrhea in Kenya.Jpn J Infect Dis. 2017 Jan 24;70(1):80-83. doi: 10.7883/yoken.JJID.2016.064.

  2. Wasito EB, Shigemura K, Osawa K, Fardah A, Kanaida A, Raharjo D, Kuntaman K, Hadi U, Harijono S, Sudarmo SM, Nakamura T, Shibayama K, Fujisawa M, Shirakawa T. Antibiotic susceptibilities and genetic characterization of extended spectrum beta-lactamase producing Escherichia coli isolated from stools of pediatric diarrhea patients in Surabaya, Indonesia. Jpn J Infect Dis. 2016 Dec 22. doi: 10.7883/yoken.JJID.2016.234.

2015

  1. Osawa K, Shigemura K, Shimizu R, Kato A, Kusuki M, Jikimoto T, Nakamura T, Yoshida H, Arakawa S, Fujisawa M, Shirakawa T. Molecular characteristics of extended-spectrum β-lactamase-producing Escherichia coli in a university teaching hospital. Microb Drug Resist. 2015 Apr;21(2):130-9. doi: 10.1089/mdr.2014.0083.
  2. Shigemura K, Osawa K, Miura M, Tanaka K, Arakawa S, Shirakawa T, Fujisawa M. Azithromycin resistance and its mechanism in Neisseria gonorrhoeae strains in Hyogo, Japan. Antimicrob Agents Chemother. 2015 May;59(5):2695-9. doi: 10.1128/AAC.04320-14.
  3. Shirakawa T. [Development of the novel oral vaccine against hepatitis C virus utilizing bifidobacteria]. Nihon Rinsho. 2015 Feb;73(2):239-42. Review. [Japanese]
  4. Sudarmo SM, Shigemura K, Athiyyah AF, Osawa K, Wardana OP, Darma A, Ranuh R, Raharjo D, Arakawa S, Fujisawa M, Shirakawa T. Genotyping and clinical factors in pediatric diarrhea caused by rotaviruses: one-year surveillance in Surabaya, Indonesia. Gut Pathog. 2015 Feb 8;7:3. doi: 10.1186/s13099-015-0048-2.
  5. Shigemura K, Osawa K, Kato A, Tokimatsu I, Arakawa S, Shirakawa T, Fujisawa M. Association of overexpression of efflux pump genes with antibiotic resistance in Pseudomonas aeruginosa strains clinically isolated from urinary tract infection patients. J Antibiot (Tokyo). 2015 Sep;68(9):568-72. doi: 10.1038/ja.2015.34.J Antibiot (Tokyo). 2015 Sep;68(9):568-72. doi: 10.1038/ja.2015.34.
  6. Tada Y, Hiroshima K, Shimada H, Morishita N, Shirakawa T, Matsumoto K, Shingyoji M, Sekine I, Tatsumi K, Tagawa M. A clinical protocol to inhibit the HGF/c-Met pathway for malignant mesothelioma with an intrapleural injection of adenoviruses expressing the NK4 gene. Springerplus. 2015 Jul 16;4:358. doi: 10.1186/s40064-015-1123-3.
  7. Yamamichi F, Shigemura K, Behnsawy HM, Yamashita M, Shirakawa T, Fujisawa M. Beta-3 adrenergic receptors could be significant factors for overactive bladder-related symptoms. Int J Clin Exp Pathol. 2015 Sep 1;8(9):11863-70.
  8. Osawa K, Shigemura K, Shirai H, Kato A, Okuya Y, Jikimoto T, Arakawa S, Fujisawa M, Shirakawa T. BACTERIAL IDENTIFICATION USING SSRA ENCODING TRANSFER-MESSENGER RNA. Southeast Asian J Trop Med Public Health. 2015 Jul;46(4):720-7.


2014

1.         Osawa K, Shigemura K, Shimizu R, Kato A, Kusuki M, Jikimoto T, Nakamura T, Yoshida H, Arakawa S, Fujisawa M, Shirakawa T. Molecular Characteristics of Extended-Spectrum β-Lactamase-Producing Escherichia coli in a University Teaching Hospital. Microb Drug Resist. 2014 Oct 31. [Epub ahead of print]

2.         Yamamichi F, Shigemura K, Behnsawy HM, Meligy FY, Huang WC, Li X, Yamanaka K, Hanioka K, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Sonic hedgehog and androgen signaling in tumor and stromal compartments drives epithelial-mesenchymal transition in prostate cancer. Scand J Urol. 2014 Dec;48(6):523-32.

3.         Saito H, Ando S, Morishita N, Lee KM, Dator D, Dy D, Shigemura K, Adhim Z,Nibu K, Fujisawa M, Shirakawa T. A combined lymphokine-activated killer (LAK) cell immunotherapy and adenovirus-p53 gene therapy for head and neck squamouscell carcinoma. Anticancer Res. 2014 Jul;34(7):3365-70.

4.         Shimizu R, Osawa K, Shigemura K, Yoshida H, Fujiwara M, Iijima Y, Fujisawa M, Shirakawa T. Development of multiplex PCR for rapid identification of four Salmonella serovars most commonly isolated in Japan. Southeast Asian J Trop Med Public Health. 2014 May;45(3):654-61.

5.         Osawa K, Shigemura K, Jikimoto T, Shirakawa T, Fujisawa M, Arakawa S. Comparison between phage-open-reading frame typing and automated repetitive-sequence-based PCR for typing MRSA isolates. J Antibiot (Tokyo). 2014  Aug;67(8):565-9. doi: 10.1038/ja.2014.41. Epub 2014 Apr 16.

6.         Takei S, Omoto C, Kitagawa K, Morishita N, Katayama T, Shigemura K, Fujisawa M, Kawabata M, Hotta H, Shirakawa T. Oral administration of genetically modified  Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice. Vaccine. 2014 May 23;32(25):3066-74.

7.         Osawa K, Shigemura K, Shimizu R, Kato A, Kimura M, Katayama Y, Okuya Y, Yutaka S, Nishimoto A, Kishi A, Fujiwara M, Yoshida H, Iijima Y, Fujisawa M, Shirakawa T. Antimicrobial resistance in Salmonella strains clinically isolated in Hyogo, Japan (2009-2012). Jpn J Infect Dis. 2014;67(1):54-7.

2013

8.         Osawa K, Raharjo D, Wasito EB, Harijono S, Shigemura K, Osawa R, Sudarmo SM, Iijima Y, Shirakawa T. Frequency of diarrheagenic Escherichia coli among children in Surabaya, Indonesia. Jpn J Infect Dis. 2013;66(5):446-8.

9.         Behnsawy HM, Shigemura K, Meligy FY, Yamamichi F, Yamashita M, Haung WC, Li X, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Possible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progression.  Korean J Urol. 2013 Aug;54(8):547-54.

10.      Osawa K, Shigemura K, Iguchi A, Shirai H, Imayama T, Seto K, Raharjo D, Fujisawa M, Osawa R, Shirakawa T. Modulation of O-antigen chain length by the wzz gene in Escherichia coli O157 influences its sensitivities to serum complement. Microbiol Immunol. 2013 Sep;57(9):616-23.

11.      Adhim Z, Otsuki N, Kitamoto J, Morishita N, Kawabata M, Shirakawa T, Nibu K. Gene silencing with siRNA targeting E6/E7 as a therapeutic intervention against head and neck cancer-containing HPV16 cell lines. Acta Otolaryngol. 2013 Jul;133(7):761-71.

12.      Shirakawa T, Haraguchi T, Shigemura K, Morishita S, Minayoshi K, Miyazaki J, Yamada Y, Miyake H, Tanaka K, Fujisawa M. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. Int J Urol. 2013 Sep;20(9):903-10.

2012

13.      Shigemura K, Tanaka K, Yamamichi F, Shirakawa T, Miyake H, Fujisawa M. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study. Int J Antimicrob Agents. 2012 Dec;40(6):516-20.

14.      Matsuoka T, Shigemura K, Yamamichi F, Fujisawa M, Kawabata M, Shirakawa T. Detection of tumor markers in prostate cancer and comparison of sensitivity between real time and nested PCR. Kobe J Med Sci. 2012 Jun 27;58(2):E51-9.

15.      Yamamichi F, Matsuoka T, Shigemura K, Kawabata M, Shirakawa T, Fujisawa M. Potential establishment of lung metastatic xenograft model of androgen receptor-positive and androgen-independent prostate cancer (C4-2B). Urology. 2012 Oct;80(4):951.e1-7.

16.      Sonn CH, Choi JR, Kim TJ, Yu YB, Kim K, Shin SC, Park GH, Shirakawa T, Kim HS, Lee KM. Augmentation of natural cytotoxicity by chronic low-dose ionizing radiation in murine natural killer cells primed by IL-2. J Radiat Res. 2012 Nov 1;53(6):823-9. doi: 10.1093/jrr/rrs037. Epub 2012 Aug 21.

17.      Matsumoto M, Shigemura K, Shirakawa T, Nakano Y, Miyake H, Tanaka K, Kinoshita S, Arakawa S, Kawabata M, Fujisawa M. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 114 clinical isolates of Pseudomonas aeruginosa derived from urinary tract infections and their rapid detection by denaturing high-performance liquid chromatography. Int J Antimicrob Agents. 2012 Nov;40(5):440-4.

18.      Meligy FY, Shigemura K, Behnsawy HM, Fujisawa M, Kawabata M, Shirakawa T. The efficiency of in vitro isolation and myogenic differentiation of MSCs derived from adipose connective tissue, bone marrow, and skeletal muscle tissue. In Vitro Cell Dev Biol Anim. 2012 Apr;48(4):203-15.

19.      Shigemura K, Tanaka K, Matsumoto M, Nakano Y, Shirakawa T, Miyata M, Yamashita M, Arakawa S, Fujisawa M. Post-operative infection and prophylactic antibiotic administration after radical cystectomy with orthotopic neobladder urinary diversion. J Infect Chemother. 2012 Aug;18(4):479-84.

20.     Adhim Z, Lin X, Huang W, Morishita N, Nakamura T, Yasui H, Otsuki N, Shigemura K, Fujisawa M, Nibu K, Shirakawa T. E10A, an adenovirus-carrying endostatin gene, dramatically increased the tumor drug concentration of metronomic chemotherapy with low-dose cisplatin in a xenograft mouse model for head and neck squamous-cell carcinoma. Cancer Gene Ther. 2012 Feb;19(2):144-52.

21.      Iguchi K, Sakurai F, Tomita K, Katayama K, Yamaguchi T, Kawabata K, Tagawa M, Kawabata M, Shirakawa T, Mizuguchi H. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells. Cancer Gene Ther. 2012 Feb;19(2):118-25.

2011

22.     Yasufuku T, Shigemura K, Shirakawa T, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Kawabata M, Fujisawa M. Mechanisms of and risk factors for fluoroquinolone resistance in clinical Enterococcus faecalis isolates from patients with urinary tract infections. J Clin Microbiol. 2011 Nov;49(11):3912-6.

23.      Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee KM, Kawabata M, Fujisawa M, Nibu K, Shirakawa T. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell  lines. Br J Cancer. 2011 Jul 26;105(3):393-402.

24.     Saito A, Morishita N, Mitsuoka C, Kitajima S, Hamada K, Lee KM, Kawabata M, Fujisawa M, Shirakawa T. Intravenous injection of irradiated tumor cell vaccine carrying oncolytic adenovirus suppressed the growth of multiple lung tumors in a  mouse squamous cell carcinoma model. J Gene Med. 2011 Jun;13(6):353-61.

25.     Nishibori T, de Vries GC, Rahardjo D, Wasito EB, De I, Kinoshita S, Hayashi Y, Hotta H, Kawabata M, Shirakawa T, Iijima Y, Osawa R. Phenotypic and genotypic  characterization of Vibrio cholerae clinically isolated in Surabaya, Indonesia. Jpn J Infect Dis. 2011;64(1):7-12.

26.     Yasufuku T, Shigemura K, Shirakawa T, Matsumoto M, Nakano Y, Tanaka K, Arakawa S, Kinoshita S, Kawabata M, Fujisawa M. Correlation of overexpression of  efflux pump genes with antibiotic resistance in Escherichia coli Strains clinically isolated from urinary tract infection patients. J Clin Microbiol. 2011 Jan;49(1):189-94.

27.      Yasufuku T, Shigemura K, Shirakawa T, Nakano Y, Tanaka K, Arakawa S, Kinoshita S, Nishimura K, Kawabata M, Fujisawa M. Risk factors and mechanisms of  fluoroquinolone resistance in 156 Escherichia coli strains clinically isolated from urinary tract infections. Scand J Infect Dis. 2011 Feb;43(2):83-8.

2010

28.     Yamamoto S, Wada J, Katayama T, Jikimoto T, Nakamura M, Kinoshita S, Lee KM, Kawabata M, Shirakawa T. Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium  in a murine typhoid fever model. Vaccine. 2010 Sep 24;28(41):6684-91.

29.     Hatta M, Ratnawati, Tanaka M, Ito J, Shirakawa T, Kawabata M. NRAMP1/SLC11A1  gene polymorphisms and host susceptibility to Mycobacterium tuberculosis and M. leprae in South Sulawesi, Indonesia. Southeast Asian J Trop Med Public Health. 2010 Mar;41(2):386-94.

30.      Bito T, Sumita N, Masaki T, Shirakawa T, Ueda M, Yoshiki R, Tokura Y, Nishigori C. Ultraviolet light induces Stat3 activation in human keratinocytes and fibroblasts through reactive oxygen species and DNA damage. Exp Dermatol. 2010 Jul 1;19(7):654-60.

2009

31.      Yanagi D, de Vries GC, Rahardjo D, Alimsardjono L, Wasito EB, De I, Kinoshita S, Hayashi Y, Hotta H, Osawa R, Kawabata M, Shirakawa T. Emergence of fluoroquinolone-resistant strains of Salmonella enterica in Surabaya, Indonesia.  Diagn Microbiol Infect Dis. 2009 Aug;64(4):422-6.

32.      Terao S, Shirakawa T, Acharya B, Miyata M, Hinata N, Tanaka K, Takenaka A, Hara I, Naoe M, Fuji K, Okegawa T, Higashihara E, Kamidono S, Fujisawa M, Gotoh A. A pilot study of quality of life of patients with hormone-refractory prostate  cancer after gene therapy. Anticancer Res. 2009 May;29(5):1533-7.

33.      Shirakawa T. Clinical trial design for adenoviral gene therapy products. Drug News Perspect. 2009 Apr;22(3):140-5. doi: 10.1358/dnp.2009.22.3.1354090. Review.

34.      Nakagawa T, Tanaka H, Shirakawa T, Gotoh A, Hayashi Y, Hamada K, Tsukuda M, Nibu K. Cyclooxygenase 2 promoter-based replication-selective adenoviral vector for hypopharyngeal cancer. Arch Otolaryngol Head Neck Surg. 2009 Mar;135(3):282-6

35.      Gardner TA, Lee SJ, Lee SD, Li X, Shirakawa T, Kwon DD, Park RY, Ahn KY, Jung C. Differential expression of osteocalcin during the metastatic progression of prostate cancer. Oncol Rep. 2009 Apr;21(4):903-8.

2008

36.      Okamura N, Masuda T, Gotoh A, Shirakawa T, Terao S, Kaneko N, Suganuma K, Watanabe M, Matsubara T, Seto R, Matsumoto J, Kawakami M, Yamamori M, Nakamura T, Yagami T, Sakaeda T, Fujisawa M, Nishimura O, Okumura K. Quantitative proteomic analysis to discover potential diagnostic markers and therapeutic targets in human renal cell carcinoma. Proteomics. 2008 Aug;8(15):3194-203.

37.      Ito J, Dung DT, Vuong MT, Tuyen do G, Vinh le D, Huong NT, Ngoc TB, Ngoc NT, Hien MT, Hao DD, Oanh LT, Lieu do T, Fujisawa M, Kawabata M, Shirakawa T. Impact and perspective on chronic kidney disease in an Asian developing country: a large-scale survey in North Vietnam. Nephron Clin Pract. 2008;109(1):c25-32.

38.      Shirakawa T. The current status of adenovirus-based cancer gene therapy. Mol Cells. 2008 Jun 30;25(4):462-6.

39.      Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, Fujisawa M, Kawabata M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology. 2008 Jan;71(1):156-60.

40.     Shirakawa T, Fujisawa M, Gotoh A. Gene therapy in prostate cancer: past, present and future. Front Biosci. 2008 Jan 1;13:2115-9. Review.

2007

41.      Shirakawa T, Terao S, Hinata N, Tanaka K, Takenaka A, Hara I, Sugimura K, Matsuo M, Hamada K, Fuji K, Okegawa T, Higashihara E, Gardner TA, Kao C, Chung LW, Kamidono S, Fujisawa M, Gotoh A. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther. 2007 Dec;18(12):1225-32.

42.     Terao S, Shirakawa T, Kubo S, Bishunu A, Lee SJ, Goda K, Tsukuda M, Hamada K, Tagawa M, Takenaka A, Fujisawa M, Gotoh A. Midkine promoter-based conditionally replicative adenovirus for targeting midkine-expressing human bladder cancer model. Urology. 2007 Nov;70(5):1009-13.

43.      Hamada K, Desaki J, Nakagawa K, Zhang T, Shirakawa T, Gotoh A, Tagawa M. Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther. 2007 Jun;15(6):1121-8.

44.     Hoshitani Y, Ishida H, Otsuki N, Shirakawa T, Gotoh A, Nibu K. Induction of immunological antitumor effects by adenovirus-mediated gene transfer of B7-1 in a murine squamous cell carcinoma cell line. Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):270-5.

2006

45.     Takata T, Shirakawa T, Ito J, Okamoto A, Massi MN, Kinoshita S, Hatta M, Kawabata M. SCCmec typing and detection of VISA-related genes in methicillin-resistant Staphylococcus aureus clinical strains from Kobe University Hospital, Japan. Southeast Asian J Trop Med Public Health. 2006 Nov;37(6):1149-55.

46.     Okada H, Shirakawa T, Gotoh A, Kamiyama Y, Muto S, Ide H, Hamaguchi Y, Horie S. Enumeration of bacterial cell numbers and detection of significant bacteriuria by use of a new flow cytometry-based device. J Clin Microbiol. 2006 Oct;44(10):3596-9.

47.      Takata T, Shirakawa T, Kawasaki Y, Kinoshita S, Gotoh A, Kano Y, Kawabata M. Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model. J Gene Med. 2006 Nov;8(11):1341-6.

48.     Hamada K, Shirakawa T, Gotoh A, Roth JA, Follen M. Adenovirus-mediated transfer of human papillomavirus 16 E6/E7 antisense RNA and induction of apoptosis in cervical cancer. Gynecol Oncol. 2006 Dec;103(3):820-30.

49.     de Carvalho CM, Zuccherato LW, Fujisawa M, Shirakawa T, Ribeiro-dos-Santos AK, Santos SE, Pena SD, Santos FR. Study of AZFc partial deletion gr/gr in fertile and infertile Japanese males. J Hum Genet. 2006;51(9):794-9.

50.     Hinata N, Shirakawa T, Terao S, Goda K, Tanaka K, Yamada Y, Hara I, Kamidono  S, Fujisawa M, Gotoh A. Progress report on phase I/II clinical trial of Ad-OC-TK  plus VAL therapy for metastatic or locally recurrent prostate cancer: Initial experience at Kobe University. Int J Urol. 2006 Jun;13(6):834-7.

51.      Miyata M, Shirakawa T, Acharya B, Terao S, Gotoh A. Effects of nafamostat mesilate on ADP-induced platelet aggregation and disaggregation in hemodialysis patients. ASAIO J. 2006 May-Jun;52(3):272-5.

52.     Shigemura K, Shirakawa T, Tanaka K, Arakawa S, Gotoh A, Fujisawa M. Rapid detection of the fluoroquinolone resistance-associated ParC mutation in Neisseria gonorrhoeae using TaqMan probes. Int J Urol. 2006 Mar;13(3):277-81.

53.      Shirakawa T, Acharya B, Kinoshita S, Kumagai S, Gotoh A, Kawabata M. Decreased susceptibility to fluoroquinolones and gyrA gene mutation in the Salmonella enterica serovar Typhi and Paratyphi A isolated in Katmandu, Nepal, in 2003. Diagn Microbiol Infect Dis. 2006 Apr;54(4):299-303.

54.     Higuchi M, Kudo T, Suzuki S, Evans TT, Sasaki R, Wada Y, Shirakawa T, Sawyer  JR, Gotoh A. Mitochondrial DNA determines androgen dependence in prostate cancer  cell lines. Oncogene. 2006 Mar 9;25(10):1437-45.

2005

55.     Shigemura K, Shirakawa T, Wada Y, Kamidono S, Fujisawa M, Gotoh A. Antitumor effects of etodolac, a selective cyclooxygenase-II inhibitor, against human prostate cancer cell lines in vitro and in vivo. Urology. 2005 Dec;66(6):1239-44.

56.     Shigemura K, Shirakawa T, Massi N, Tanaka K, Arakawa S, Gotoh A, Fujisawa M. Presence of a mutation in ponA1 of Neisseria gonorrhoeae in numerous clinical samples resistant to various beta-lactams and other, structurally unrelated, antimicrobials. J Infect Chemother. 2005 Oct;11(5):226-30.

57.      Sakaeda T, Okamura N, Gotoh A, Shirakawa T, Terao S, Morioka M, Tokui K, Tanaka H, Nakamura T, Yagi M, Nishimura Y, Yokoyama M, Okumura K. EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res. 2005 Oct;22(10):1757-61. Epub 2005 Sep 22. PubMed PMID: 16180134.

58.     Terao S, Shirakawa T, Goda K, Kamidono S, Fujisawa M, Gotoh A. Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model. Anticancer Res. 2005 Jul-Aug;25(4):2757-60.

59.     Tanaka H, Shirakawa T, Zhang Z, Hamada K, Gotoh A, Nibu K. A replication-selective adenoviral vector for head and neck cancers. Arch Otolaryngol Head Neck Surg. 2005 Jul;131(7):630-4. Erratum in: Arch Otolaryngol Head Neck Surg. 2005 Oct;131(10):920.

60.     Massi MN, Shirakawa T, Gotoh A, Bishnu A, Hatta M, Kawabata M. Quantitative detection of Salmonella enterica serovar Typhi from blood of suspected typhoid fever patients by real-time PCR. Int J Med Microbiol. 2005 Jun;295(2):117-20..

61.      Terao S, Yamada Y, Shirakawa T, Hara I, Kanomata N, Kamidono S. Granulocyte-colony stimulating factor producing urothelial carcinoma of renal pelvis. Int J Urol. 2005 May;12(5):500-2.

62.     Massi MN, Shirakawa T, Gotoh A, Hatta M, Kawabata M. Identification and sequencing of Salmonella enterica serotype typhi isolates obtained from patients  with perforation and non-perforation typhoid fever. Southeast Asian J Trop Med Public Health. 2005 Jan;36(1):118-22.

63.      Matsumoto Y, Morimoto I, Shibutani T, Mukubou M, Shirakawa T, Gotoh A, Kawabata M. Measles encephalitis in early pregnancy and after delivery. J Infect Chemother. 2005 Apr;11(2):97-100.

64.     Shigemura K, Shirakawa T, Okada H, Tanaka K, Kamidono S, Arakawa S, Gotoh A. Rapid detection and differentiation of Gram-negative and Gram-positive pathogenic bacteria in urine using TaqMan probe. Clin Exp Med. 2005 Mar;4(4):196-201.

65.     Acharya B, Shirakawa T, Pungky A, Damanik P, Massi MN, Miyata M, Matsuo M, Gotoh A. Polymorphism of the interleukin-4, interleukin-13, and signal transducer and activator of transcription 6 genes in Indonesian children with minimal change nephrotic syndrome. Am J Nephrol. 2005 Jan-Feb;25(1):30-5.

2004

66.     Hinata N, Shirakawa T, Okada H, Shigemura K, Kamidono S, Gotoh A. Quantitative detection of Escherichia coli from urine of patients with bacteriuria by real-time PCR. Mol Diagn. 2004;8(3):179-84.

67.      Yamamori M, Sakaeda T, Nakamura T, Okamura N, Tamura T, Aoyama N, Kamigaki T, Ohno M, Shirakawa T, Gotoh A, Kuroda Y, Matsuo M, Kasuga M, Okumura K. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun. 2004 Dec 3;325(1):144-50.

68.     Gotoh A, Goto K, Sengoku A, Shirakawa T, Akao Y, Fujisawa M, Okada H, Arakawa S, Kamidono S. Inhibition mechanism of Gosha-jinki-gan on the micturition reflex in rats. J Pharmacol Sci. 2004 Oct;96(2):115-23.

69.     Shigemura K, Shirakawa T, Okada H, Tanaka K, Udaka T, Kamidono S, Arakawa S, Gotoh A. Rapid detection of gyrA and parC mutations in fluoroquinolone-resistant  Neisseria gonorrhoeae by denaturing high-performance liquid chromatography. J Microbiol Methods. 2004 Dec;59(3):415-21.

70.      Goda K, Fujisawa M, Shirakawa T, Dobashi M, Shiota G, Zhang ZJ, Gotoh A, Kamidono S. Adenoviral-mediated HGF expression inhibits germ cell apoptosis in rats with cryptorchidism. J Gene Med. 2004 Aug;6(8):869-76.

71.      Gotoh A, Sakaeda T, Kimura T, Shirakawa T, Wada Y, Wada A, Kimachi T, Takemoto Y, Iida A, Iwakawa S, Hirai M, Tomita H, Okamura N, Nakamura T, Okumura  K. Antiproliferative activity of Rhinacanthus nasutus (L.) Kurz extracts and the active moiety, Rhinacanthin C. Biol Pharm Bull. 2004 Jul;27(7):1070-4.

72.      Shirakawa T, Hamada K, Zhang Z, Okada H, Tagawa M, Kamidono S, Kawabata M, Gotoh A. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin Cancer Res. 2004 Jul 1;10(13):4342-8.

73.      Okada H, Shirakawa T, Ishikawa T, Goda K, Fujisawa M, Kamidono S. Serum testosterone levels in patients with nonmosaic Klinefelter syndrome after testicular sperm extraction for intracytoplasmic sperm injection. Fertil Steril.  2004 Jul;82(1):237-8.

74.      Hinata N, Shirakawa T, Okada H, Achaya B, Kamidono S, Gotoh A. Quantitative analysis of the levels of expression of muscarinic receptor subtype RNA in the detrusor muscle of patients with overactive bladder. Mol Diagn. 2004;8(1):17-22. 

75.      Gotoh A, Shirakawa T, Hinata N, Wada Y, Hara I, Fujisawa M, Kawabata G, Okada H, Arakawa S, Kamidono S. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma. Int J Urol. 2004 May;11(5):257-63.

76.      Shigemura K, Shirakawa T, Okada H, Hinata N, Acharya B, Kinoshita S, Kofuku T, Kawabata M, Kamidono S, Arakawa S, Gotoh A. Mutations in the gyrA and parC genes and in vitro activities of fluoroquinolones in 91 clinical isolates of Neisseria gonorrhoeae in Japan. Sex Transm Dis. 2004 Mar;31(3):180-4.

77.      Nakahara T, Sakaeda T, Nakamura T, Tamura T, Nishioka C, Aoyama N, Okamura N, Shirakawa T, Gotoh A, Kamigaki T, Ohno M, Kuroda Y, Matsuo M, Kasuga M, Okumura K. Chemosensitivity assessed by collagen gel droplet embedded culture drug sensitivity test, and MDR1, MRP1, and MRP2 mRNA expression in human colorectal adenocarcinomas. Pharm Res. 2004 Mar;21(3):406-12.

78.      Shigemura K, Okada H, Shirakawa T, Tanaka K, Arakawa S, Kinoshita S, Gotoh A, Kamidono S. Susceptibilities of Neisseria gonorrhoeae to fluoroquinolones and other antimicrobial agents in Hyogo and Osaka, Japan. Sex Transm Infect. 2004 Apr;80(2):105-7.

79.      Shirakawa T, Gotoh A, Zhang Z, Kao C, Chung LW, Gardner TA. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer. Urology. 2004 Mar;63(3):613-8.

80.     Shirakawa T, Okada H, Acharya B, Zhang Z, Hinata N, Wada Y, Uji T, Kamidono S, Gotoh A. Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate. 2004 Jan 1;58(1):33-40.

2003

81.      Matsuo T, Shirakawa T, Singhasivanon P, Looareesuwan S, Kawabata M. Effects of mefloquine usage on genetic polymorphism of Plasmodium falciparum in Thai-Myanmarese border. Kobe J Med Sci. 2003;49(5-6):143-51.

82.     Zhang Z, Shirakawa T, Hinata N, Matsumoto A, Fujisawa M, Okada H, Kamidono S, Matsuo M, Gotoh A. Combination with CD/5-FC gene therapy enhances killing of human bladder-cancer cells by radiation. J Gene Med. 2003 Oct;5(10):860-7..

83.      Massi MN, Shirakawa T, Gotoh A, Bishnu A, Hatta M, Kawabata M. Rapid diagnosis of typhoid fever by PCR assay using one pair of primers from flagellin  gene of Salmonella typhi. J Infect Chemother. 2003 Sep;9(3):233-7.

84.     Hinata N, Shirakawa T, Zhang Z, Matsumoto A, Fujisawa M, Okada H, Kamidono S, Gotoh A. Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells. Urol Res. 2003 Dec;31(6):387-96.

85.     Gotoh A, Shirakawa T, Wada Y, Fujisawa M, Okada H, Kamidono S, Hamada K. The growth inhibitory effect of p21 adenovirus on androgen-dependent and –independent human prostate cancer cells. BJU Int. 2003 Aug;92(3):314-8.

86.     Zhou A, Ueno H, Shimomura M, Tanaka R, Shirakawa T, Nakamura H, Matsuo M, Iijima K. Blockade of TGF-beta action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int. 2003 Jul;64(1):92-101.

87.      Okada H, Shirakawa T, Miyake H, Gotoh A, Fujisawa M, Arakawa S, Kamidono S. Establishment of a prostatic small-cell carcinoma cell line (SO-MI). Prostate. 2003 Aug 1;56(3):231-8.

88.     Shirakawa T, Fujisawa M, Gotoh A, Okada H, Arakawa S, Kamidono S. Complete resection of synovial sarcoma of prostatic fascia. Urology. 2003 Mar;61(3):644.

89.     Nakumura T, Sakaeda T, Ohmoto N, Moriya Y, Komoto C, Shirakawa T, Gotoh A, Matsuo M, Okmura K. Gene expression profiles of ABC transporters and cytochrome P450 3A in Caco-2 and human colorectal cancer cell lines. Pharm Res. 2003 Feb;20(2):324-7.

90.     Carvalho CM, Fujisawa M, Shirakawa T, Gotoh A, Kamidono S, Freitas Paulo T, Santos SE, Rocha J, Pena SD, Santos FR. Lack of association between Y chromosome  haplogroups and male infertility in Japanese men. Am J Med Genet A. 2003 Jan 15;116A(2):152-8.

2002

91.      Gotoh A, Goto K, Sengoku A, Shirakawa T, Akao Y, Fujisawa M, Okada H, Arakawa S, Sasaki H, Kamidono S. Inhibition of urinary bladder motility by a spinal action of U-50488H in rats. J Pharm Pharmacol. 2002 Dec;54(12):1645-50.

92.     Sakaeda T, Nakamura T, Hirai M, Kimura T, Wada A, Yagami T, Kobayashi H, Nagata S, Okamura N, Yoshikawa T, Shirakawa T, Gotoh A, Matsuo M, Okumura K. MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res. 2002 Sep;19(9):1323-9.

93.      Moriya Y, Nakamura T, Horinouchi M, Sakaeda T, Tamura T, Aoyama N, Shirakawa T, Gotoh A, Fujimoto S, Matsuo M, Kasuga M, Okumura K. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull. 2002 Oct;25(10):1356-9.

94.     Bito T, Roy S, Sen CK, Shirakawa T, Gotoh A, Ueda M, Ichihashi M, Packer L. Flavonoids differentially regulate IFN gamma-induced ICAM-1 expression in human keratinocytes: molecular mechanisms of action. FEBS Lett. 2002 Jun 5;520(1-3):145-52.

95.     Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, Matsuo M, Kasuga M, Okumura K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002 Apr;71(4):297-303.

96.     Matsubara S, Okada H, Shirakawa T, Gotoh A, Kuno T, Kamidono S. Estrogen levels influence beta-3-adrenoceptor-mediated relaxation of the female rat detrusor muscle. Urology. 2002 Apr;59(4):621-5.

97.      Nakamura T, Sakaeda T, Ohmoto N, Tamura T, Aoyama N, Shirakawa T, Kamigaki T, Nakamura T, Kim KI, Kim SR, Kuroda Y, Matsuo M, Kasuga M, Okumura K. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. Drug Metab Dispos. 2002 Jan;30(1):4-6.

2001

98.     Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol  Phys. 2001 Dec 1;51(5):1336-45.

99.     Wada Y, Gotoh A, Shirakawa T, Hamada K, Kamidono S. Gene therapy for bladder cancer using adenoviral vector. Mol Urol. 2001 Summer;5(2):47-52.

100.  Shirakawa T, Sasaki R, Gardner TA, Kao C, Zhang ZJ, Sugimura K, Matsuo M, Kamidono S, Gotoh A. Drug-resistant human bladder-cancer cells are more sensitive to adenovirus-mediated wild-type p53 gene therapy compared to drug-sensitive cells. Int J Cancer. 2001 Oct 15;94(2):282-9.

101.   Fujisawa M, Shirakawa T, Kanzaki M, Okada H, Arakawa S, Kamidono S. Y-chromosome microdeletion and phenotype in cytogenetically normal men with idiopathic azoospermia. Fertil Steril. 2001 Sep;76(3):491-5.

102.  Fujisawa M, Shirakawa T, Fujioka H, Gotoh A, Okada H, Arakawa S, Kamidono S. Adenovirus-mediated p53 gene transfer to rat testis impairs spermatogenesis. Arch Androl. 2001 May-Jun;46(3):223-31.

2000

103.   Shirakawa T, Gotoh A, Wada Y, Kamidono S, Ko SC, Kao C, Gardner TA, Chung LW. Tissue-specific promoters in gene therapy for the treatment of prostate cancer. Mol Urol. 2000 Summer;4(2):73-82. Review..

104.  Shirakawa T, Gotoh A, Gardner TA, Kao C, Zhang ZJ, Matsubara S, Wada Y, Hinata N, Fujisawa M, Hanioka K, Matsuo M, Kamidono S. p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model. J Gene Med. 2000 Nov-Dec;2(6):426-32.

1999

105.  Shirakawa T, Gardner TA, Ko SC, Bander N, Woo S, Gotoh A, Kamidono S, Chung LW, Kao C. Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. J Urol. 1999 Sep;162(3 Pt 1):949-54.

1998

106.  Shirakawa T, Ko SC, Gardner TA, Cheon J, Miyamoto T, Gotoh A, Chung LW, Kao C. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy. Cancer Gene Ther. 1998 Sep-Oct;5(5):274-80.

107.   Gotoh A, Ko SC, Shirakawa T, Cheon J, Kao C, Miyamoto T, Gardner TA, Ho LJ, Cleutjens CB, Trapman J, Graham FL, Chung LW. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer. J Urol. 1998 Jul;160(1):220-9.

108.  Gotoh A, Hanioka K, Shirakawa T, Wada Y, Gohji K, Okada H, Arakawa S, Kamidono S. Assessment of proliferating cell nuclear antigen expression and prognosis in patients with renal cell carcinoma with pulmonary metastases. Int J  Urol. 1998 May;5(3):214-8.

1997

109.  Cheon J, Ko SC, Gardner TA, Shirakawa T, Gotoh A, Kao C, Chung LW. Chemogene therapy: osteocalcin promoter-based suicide gene therapy in combination with methotrexate in a murine osteosarcoma model. Cancer Gene Ther. 1997 Nov-Dec;4(6):359-65.

110.   Shirakawa T, Fujisawa M, Kanzaki M, Okada H, Arakawa S, Kamidono S. Y chromosome (Yq11) microdeletions in idiopathic azoospermia. Int J Urol. 1997 Mar;4(2):198-201..

1996

111.   Ko SC, Cheon J, Kao C, Gotoh A, Shirakawa T, Sikes RA, Karsenty G, Chung LW. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 1996 Oct 15;56(20):4614-9.

112.   Okada H, Iwamoto T, Fujioka H, Shirakawa T, Tatsumi N, Kanzaki M, Minayoshi K, Ohya K, Fujisawa M, Arakawa S, Kamidono S, Ishigami J. Hyperprolactinaemia among infertile patients and its effect on sperm functions. Andrologia. 1996 Jul-Aug;28(4):197-202.

 

 

Navigation

Links

Regulatory Pathway for the Development of Advanced therapy
Presented at 2011 JSGT, Fukuoka,JAPAN Guideline_poster201107.pdf